Bluefish Pharmaceuticals AB:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bluefish Pharmaceuticals AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10509
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bluefish Pharmaceuticals AB (Bluefish Pharmaceuticals) is a pharmaceutical company that develops, manufactures and distributes generic pharmaceuticals. The company offers products in the therapeutic areas of cardiovascular, central nervous system, gastrointestinal, diabetes, oncology, dermatology, respiratory, inflammatory, genito-urinary, antifungal, antiviral, endocrinology, analgesic and antibiotics, among others. Its product development process includes product selection, geographic access, costs, supply chain operations and intellectual property rights. Bluefish Pharmaceuticals’s areas of interest comprise formulation development, in-licensing of products, manufacturing, and distribution agreements. It has collaboration with development and manufacturing companies. The company caters to pharmacies, pharmacy chains, wholesalers, and government and private institutions. Bluefish Pharmaceuticals is headquartered in Stockholm, Sweden.

Bluefish Pharmaceuticals AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Bluefish Pharma Enters Into Licensing Agreement For Two Products 10
Equity Offering 11
Bluefish Pharma Completes Private Placement Of Shares For US$6.2 Million 11
Bluefish Pharma Completes Private Placement Of Shares For US$11.8 Million 12
Bluefish Pharmaceuticals AB – Key Competitors 13
Bluefish Pharmaceuticals AB – Key Employees 14
Bluefish Pharmaceuticals AB – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Recent Developments 17
Strategy And Business Planning 17
May 11, 2018: Bluefish Pharmaceuticals Expands European Footprint With Office Opening In Ireland 17
Financial Announcements 18
Aug 29, 2018: Bluefish Pharmaceuticals: Interim Report 18
Nov 20, 2017: Bluefish Pharmaceuticals: Interim Report January-September 2017 22
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Key Facts 2
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bluefish Pharmaceuticals AB, Deals By Therapy Area, 2012 to YTD 2018 8
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bluefish Pharma Enters Into Licensing Agreement For Two Products 10
Bluefish Pharma Completes Private Placement Of Shares For US$6.2 Million 11
Bluefish Pharma Completes Private Placement Of Shares For US$11.8 Million 12
Bluefish Pharmaceuticals AB, Key Competitors 13
Bluefish Pharmaceuticals AB, Key Employees 14
Bluefish Pharmaceuticals AB, Subsidiaries 15

List of Figures
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bluefish Pharmaceuticals AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Bluefish Pharmaceuticals AB:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Majestic Wine plc (WINE):企業の財務・戦略的SWOT分析
    Majestic Wine plc (WINE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Concert Pharmaceuticals Inc (CNCE):製薬・医療:M&Aディール及び事業提携情報
    Summary Concert Pharmaceuticals Inc (Concert Pharmaceuticals) is a clinical stage biotechnology company which discovers and develops small molecule drugs. The company develops its products using its deuterated chemical entity (DCE) platform to develop novel therapeutics for autoimmune and inflammato …
  • Sysmex Corp (6869):医療機器:M&Aディール及び事業提携情報
    Summary Sysmex Corp (Sysmex) is a supplier of medical devices. It researches, develops, manufactures and sells instruments, reagents, and software applications that facilitate health checkups, treatment and disease management. The company offers diagnostic instruments, reagents and laboratory inform …
  • ASFINAG:企業の戦略・SWOT・財務情報
    ASFINAG - Strategy, SWOT and Corporate Finance Report Summary ASFINAG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Sinopharm Group Co Ltd (1099):企業の財務・戦略的SWOT分析
    Sinopharm Group Co Ltd (1099) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Proteome Sciences Plc (PRM):企業の製品パイプライン分析
    Summary Proteome Sciences Plc (Proteome Sciences) is a life sciences company that delivers content for personalized medicine through biomarkers, reagents and services. Its proteomics services include drug development, biomarker discovery, quality management and provision of data insights. The compan …
  • SuanFarma SA:製薬・医療:M&Aディール及び事業提携情報
    Summary SuanFarma SA (SuanFarma Group) is a drug development company that offers production, development, and marketing of raw materials and finished dosage forms. The company’s products portfolio includes amoxiciline capsules, enalapril tablets, colistin methanesulphonate, azitromicine film coated …
  • Minoan Group Plc:企業の戦略・SWOT・財務情報
    Minoan Group Plc - Strategy, SWOT and Corporate Finance Report Summary Minoan Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • ImmunoGen, Inc.:企業のM&A・事業提携・投資動向
    ImmunoGen, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ImmunoGen, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Asarina Pharma AB-製薬・医療分野:企業M&A・提携分析
    Summary Asarina Pharma AB (Asarina Pharma), formerly Umecrine Mood AB, a subsidiary of Umecrine AB is a drug development company that concentrates on the discovery, development and commercialization of novel treatments for women suffering from premenstrual dysphoric disorder and other menstrual cycl …
  • Spur Corporation Limited:企業の戦略・SWOT・財務分析
    Spur Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Spur Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Berjaya Sports Toto Berhad:企業の戦略・SWOT・財務情報
    Berjaya Sports Toto Berhad - Strategy, SWOT and Corporate Finance Report Summary Berjaya Sports Toto Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • salesforce.com, inc.:企業のM&A・事業提携・投資動向
    salesforce.com, inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's salesforce.com, inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Traverse Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Traverse Biosciences Inc (Traverse Biosciences) is an privately held bioscience company that commercializes drug candidates for the treatment of inflammatory diseases and age-related conditions affecting humans and companion animals. The company provides lead candidate TRB-N0224 which is dev …
  • Exxon Mobil Corporation (XOM)-石油・ガス分野:企業M&A・提携分析
    Summary Exxon Mobil Corporation (ExxonMobil) is an integrated oil and gas company that explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petroleum products; and markets natural gas and natural gas liquids. It is a major manufactu …
  • Prysmian SpA (PRY):電力:M&Aディール及び事業提携情報
    Summary Prysmian SpA (Prysmian) is a provider of cables and systems. It designs, develops, manufactures, supplies, and installs cables for a wide range of applications. The company produces high- and medium voltage cable systems; high and extra high voltage cables; optical fiber, optical cables, opt …
  • Ilana Jivago Inc.:企業の戦略・SWOT・財務情報
    Ilana Jivago Inc. - Strategy, SWOT and Corporate Finance Report Summary Ilana Jivago Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Excelerate Energy LP:石油・ガス:M&Aディール及び事業提携情報
    Summary Excelerate Energy LP (Excelerate) is an oil and gas company that offers floating LNG regasification solutions. The company’s services include LNG storage and supply, floating regasification, LNG marketing and chartering, shipping and operations, and floating liquefaction services. It owns an …
  • The Housing Bank for Trade and Finance:企業の戦略・SWOT・財務分析
    The Housing Bank for Trade and Finance - Strategy, SWOT and Corporate Finance Report Summary The Housing Bank for Trade and Finance - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Phio Pharmaceuticals Corp (RXII):企業の財務・戦略的SWOT分析
    Summary Phio Pharmaceuticals Corp (Phio Pharmaceuticals), formerly known as RXi Pharmaceuticals Corp, is a biotechnology company. It discovers, develops and commercializes immuno-oncology therapeutics based RNAi platform to treat cancer. Its product pipeline includes PH-762, PH-894 and PH-804 for ad …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆